NASDAQ: EVAXEvaxion Biotech A Stock
$2.60-0.03 (-1.14%)
Updated Oct 11, 2024
EVAX Price
$2.60
Fair Value Price
-$1.72
Market Cap
$14.07M
52 Week Low
$2.26
52 Week High
$13.61
P/E
-0.58x
P/B
11.23x
P/S
39.53x
PEG
N/A
Dividend Yield
N/A
Revenue
$278.00k
Earnings
-$15.21M
Gross Margin
100%
Operating Margin
-4,544.6%
Profit Margin
-5,469.4%
Debt to Equity
11.16
Operating Cash Flow
-$15M
Beta
0.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EVAX Overview
Evaxion Biotech A/S develops novel immunotherapies to treat various cancers, bacterial diseases, and viral infections suing proprietary AI platforms (PIONEER, EDEN, and RAVENTM). The company's drug candidates include EVX-01, EVX-02, and EVX-03. Evaxion Biotech A/S has collaboration agreements with the National Center at Herlev Hospital, the Department of Health Technology at Danish Technical University, and other institutions. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EVAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVAX ($2.60) is overvalued by 251.18% relative to our estimate of its Fair Value price of -$1.72 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EVAX ($2.60) is not significantly undervalued (251.18%) relative to our estimate of its Fair Value price of -$1.72 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EVAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EVAX due diligence checks available for Premium users.
Be the first to know about important EVAX news, forecast changes, insider trades & much more!
EVAX News
Valuation
EVAX fair value
Fair Value of EVAX stock based on Discounted Cash Flow (DCF)
Price
$2.60
Fair Value
-$1.72
Undervalued by
251.18%
EVAX ($2.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EVAX ($2.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EVAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EVAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.58x
Industry
-121.69x
Market
27.31x
EVAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.23x
Industry
6.1x
EVAX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EVAX's financial health
Profit margin
Revenue
$154.0k
Net Income
-$6.2M
Profit Margin
-4,024.7%
EVAX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
EVAX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$15.2M
Liabilities
$14.0M
Debt to equity
11.16
EVAX's short-term assets ($10.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVAX's short-term assets ($10.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
EVAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EVAX vs Biotech Stocks
Evaxion Biotech A Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.